THCV vs CBG: Two Different Actions
Sellers like to file THCV beside CBG under "non-intoxicating", and only one of the two has earned the label. CBG doesn't get anyone high. THCV may, and the dose decides: in laboratory and animal work it blocks CB₁ at lower doses and can switch the same receptor on at higher ones, and nobody has established the dose at which that switch happens in people. Demonstrated · in vitro
Every statement below carries the grade its evidence has earned. Legal notes are general and dated, not legal advice. We make no therapeutic claim for either compound.
At a glance
| Attribute | THCV — tetrahydrocannabivarin | CBG — cannabigerol |
|---|---|---|
| Intoxicating? | THCV — tetrahydrocannabivarinDepends on dose, so it cannot be sold as reliably non-intoxicating (Pertwee 2008) · Demonstrated · in vitro | CBG — cannabigerolNo · Established |
| CB₁ receptor (laboratory) | THCV — tetrahydrocannabivarinBlocks CB₁; in animals, activates it at higher doses (Pertwee 2008) · Demonstrated · in vitro | CBG — cannabigerolBlocks it as a competitive antagonist (Cascio 2010) · Demonstrated · in vitro |
| Molecular formula | THCV — tetrahydrocannabivarinC₁₉H₂₆O₂ (CAS 31262-37-0) | CBG — cannabigerolC₂₁H₃₂O₂ (CAS 25654-31-3) |
| Side chain | THCV — tetrahydrocannabivarinThree-carbon propyl chain, which makes it a "varin" | CBG — cannabigerolFive-carbon pentyl chain |
| Human evidence | THCV — tetrahydrocannabivarinNo primary evidence in our registry that THCV changes a person's appetite or body weight · No primary evidence | CBG — cannabigerolA single controlled human trial, on anxiety and stress (Cuttler 2024) · Low |
| US legal status (general, dated; not legal advice) | THCV — tetrahydrocannabivarinLess settled: rests on the 2018 Farm Bill and on total-THC rules that are still changing; varies by state | CBG — cannabigerolHemp-derived CBG is generally legal federally at ≤0.3% Δ⁹-THC (2018 Farm Bill); varies by state |
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- THCV: blocks, and at higher doses activates (direction reverses with dose), in a review, no rung of its own study type: Review Pertwee 2008. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
- CB2 cannabinoid receptor
- THCV: activates (partial agonist; an earlier paper reports the opposite), in a review, no rung of its own study type: Review Pertwee 2008. CBG: no graded interaction in our registry.
- α2-adrenoceptor
- THCV: no graded interaction in our registry. CBG: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
- 5-HT1A serotonin receptor
- THCV: no graded interaction in our registry. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010.
- TRPV1 and TRPV2 ion channels
- THCV: no graded interaction in our registry. CBG: activates, then desensitises (agonist, then desensitiser; drawn as a chevron with a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
- TRPM8 ion channel
- THCV: no graded interaction in our registry. CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011.
What the evidence supports
- Intoxication. Start here, because it is where the two part company. CBG is non-intoxicating. THCV is harder to pin down: in living animals it acts as a CB₁ antagonist, and at higher doses as a CB₁ agonist (Pertwee 2008), so a THCV product sold as non-intoxicating at any strength is promising more than the data show. Demonstrated · in vitro
- Both block CB₁ first. At the doses studied in the lab, the two start out on the same side of the receptor. CBG blocks CB₁ as a competitive antagonist (Cascio 2010); THCV gets there by opposing cannabinoid agonists (Pertwee 2008). Demonstrated · in vitro
- Different families. Chemically they hang on different branches. THCV, C₁₉H₂₆O₂, is THC's propyl ("varin") cousin; CBG, C₂₁H₃₂O₂, is the neutral form of CBGA, the acid often called the plant's "mother" cannabinoid. Established
- THCV and appetite. THCV sells as "diet weed", and the nickname is running ahead of the science: our registry holds no primary evidence that it changes a person's appetite or body weight. No primary evidence
- CBG in people. CBG's human record is thinner than its shelf presence suggests: one small, acute controlled trial on anxiety and stress (Cuttler 2024) is the whole human effect record for CBG in our registry so far. Low
Common questions
Does THCV get you high like CBG doesn't?
THCV might, depending on the dose; CBG is the sober half of the pair. In lab studies THCV blocks CB₁, yet in living animals it can activate the same receptor at higher doses (Pertwee 2008). Nobody has established where that switch sits in humans, which is why a THCV product carries an intoxication risk that a CBG one avoids. Demonstrated · in vitro
Is THCV an appetite suppressant, and is CBG?
The evidence has not established either one as an appetite suppressant. THCV is sold on exactly that promise, yet our registry holds no primary evidence that it moves a person's appetite or body weight, and we make no appetite claim for CBG. An appetite line on either label is running on hope. Not medical advice. No primary evidence
Which has more human evidence, THCV or CBG?
Neither has much. CBG can point to one controlled human trial in our registry, on anxiety and stress (Cuttler 2024), graded Low. THCV's most famous promise, appetite, has no primary evidence behind it in our registry at all. Low
Are THCV and CBG legal?
In the US they often are, with caveats. Hemp-derived CBG at ≤0.3% Δ⁹-THC is generally legal federally under the 2018 Farm Bill. THCV sits in greyer territory, because the total-THC rules it leans on are still being rewritten. Both vary by state. General information, not legal advice. [Legal snapshot · not legal advice]
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Sources
- Pertwee et al. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. PMID 17828291.
- Cascio et al. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol. PMID 20002104.
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons